Literature DB >> 23394818

Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis.

A C Pettit1, J Cummins, L A Kaltenbach, T R Sterling, J V Warkentin.   

Abstract

SETTING: A key program performance objective established by the Centers for Disease Control and Prevention (CDC) is that ≥93% of tuberculosis (TB) cases complete treatment within 12 months.
OBJECTIVE: To determine the rate of and risk factors for delay in anti-tuberculosis treatment completion.
DESIGN: Nested case-control study among TB cases reported to the Tennessee Department of Health between 1 January 2000 and 31 December 2010. Time to complete treatment was calculated using treatment start and stop dates documented in the Tuberculosis Information Management System (TIMS).
RESULTS: Of 2627 cases, 261 (9.9%) required >12 months to complete treatment. In adjusted conditional logistic regression analyses, cavitary disease and positive cultures after 2 months of therapy (OR 5.85, 95%CI 1.98-17.32, P = 0.001), non-adherence (OR 4.13, 95%CI 1.76-9.72, P < 0.001), and interruptions in treatment due to drug-related issues (OR 6.91, 95%CI 3.76-12.70, P < 0.001) were independently associated with delay in completion of TB treatment.
CONCLUSION: From 2000 to 2010, the proportion of TB cases completing treatment within 12 months increased from 84.6% to 94.9%, and remained above the CDC target during 2009-2010. Efforts to improve patient adherence and reduce interruptions in treatment due to anti-tuberculosis drug-related issues could improve the proportion of TB cases completing treatment within 12 months.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394818      PMCID: PMC3981539          DOI: 10.5588/ijtld.12.0133

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  21 in total

1.  Treatment of tuberculosis.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2003-06-20

2.  Hepatotoxicity of antituberculosis drugs.

Authors:  L P Ormerod; C Skinner; J Wales
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

3.  Low antituberculosis drug concentrations in patients with AIDS.

Authors:  C A Peloquin; A T Nitta; W J Burman; K F Brudney; J R Miranda-Massari; M E McGuinness; S E Berning; G T Gerena
Journal:  Ann Pharmacother       Date:  1996-09       Impact factor: 3.154

4.  Completeness and timeliness of tuberculosis case reporting. A multistate study.

Authors:  A B Curtis; E McCray; M McKenna; I M Onorato
Journal:  Am J Prev Med       Date:  2001-02       Impact factor: 5.043

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  The effects of increasing incentives on adherence to tuberculosis directly observed therapy.

Authors:  H Davidson; N W Schluger; P H Feldman; D P Valentine; E E Telzak; F N Laufer
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

Review 7.  When tuberculosis treatment fails. A social behavioral account of patient adherence.

Authors:  E Sumartojo
Journal:  Am Rev Respir Dis       Date:  1993-05

8.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

9.  Comprehensive tuberculosis control for patients at high risk for noncompliance.

Authors:  N Schluger; C Ciotoli; D Cohen; H Johnson; W N Rom
Journal:  Am J Respir Crit Care Med       Date:  1995-05       Impact factor: 21.405

10.  Pharmacy data for tuberculosis surveillance and assessment of patient management.

Authors:  Deborah S Yokoe; Steven W Coon; Rachel Dokholyan; Michael C Iannuzzi; Timothy F Jones; Sarah Meredith; Marisa Moore; Lynelle Phillips; Wayne Ray; Stephanie Schech; Deborah Shatin; Richard Platt
Journal:  Emerg Infect Dis       Date:  2004-08       Impact factor: 6.883

View more
  5 in total

1.  Psychological and Educational Intervention to Improve Tuberculosis Treatment Adherence in Ethiopia Based on Health Belief Model: A Cluster Randomized Control Trial.

Authors:  Habteyes Hailu Tola; Davoud Shojaeizadeh; Azar Tol; Gholamreza Garmaroudi; Mir Saeed Yekaninejad; Abebaw Kebede; Luche Tadesse Ejeta; Desta Kassa; Eveline Klinkenberg
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

2.  Risk factors for early TB treatment interruption among newly diagnosed patients in Malaysia.

Authors:  Qudsiah Suliman; Poh Ying Lim; Salmiah Md Said; Kit-Aun Tan; Nor Afiah Mohd Zulkefli
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.379

3.  Effects of sociodemographic characteristics and patients' health beliefs on tuberculosis treatment adherence in Ethiopia: a structural equation modelling approach.

Authors:  Habteyes Hailu Tola; Mehrdad Karimi; Mir Saeed Yekaninejad
Journal:  Infect Dis Poverty       Date:  2017-12-15       Impact factor: 4.520

4.  The Effect of Psychosocial Factors and Patients' Perception of Tuberculosis Treatment Non-Adherence in Addis Ababa, Ethiopia.

Authors:  Habteyes Hailu Tola; Gholamreza Garmaroudi; Davoud Shojaeizadeh; Azar Tol; Mir Saeed Yekaninejad; Luche Tadesse Ejeta; Abebaw Kebede; Desta Kassa
Journal:  Ethiop J Health Sci       Date:  2017-09

5.  Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors.

Authors:  Mohammed S Al-Shahrani; Majed I Hakami; Mahmoud A Younis; Hanan A Fan; Mohammed A Jeraiby; Yasser Alraey
Journal:  Saudi Med J       Date:  2021-07       Impact factor: 1.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.